Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone
Rhea-AI Summary
Veri Medtech (VRHI) announced reaching a significant milestone of $100 million in cumulative revenue since its 2017 inception, with Q1 2025 revenue of $3.3 million. The healthcare technology platform has achieved several key milestones, including reaching up to 400,000 patients and 400 physicians on its network. The company has recently relaunched two key platforms: Veriheal.com and DosePop.com, as part of its telehealth diversification strategy. VRHI has also retained a PCAOB auditor in preparation for a potential uplisting. The company positions itself to compete with LifeMD, Ro, and HIMS in the $114 billion telehealth market through its Infinite Wellness Loop platform.
Positive
- Achieved $100 million cumulative revenue milestone since 2017
- Growing network with 400,000 patients and 400 physicians
- Strategic expansion through relaunch of two platforms: Veriheal.com and DosePop.com
- Preparation for uplisting with PCAOB auditor retention
Negative
- Q1 2025 revenue of $3.3M suggests relatively small quarterly revenue compared to established competitors
- Faces significant competition from established players like LifeMD, Ro, and HIMS
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology platform, announced today that
Additional Key Accomplishments:
- Retained PCAOB Auditor (in preparation for uplisting)
- Announced up to 400,000 Patients Milestone
- Announced up to 400 Physicians Milestone
- Relaunched Veriheal.com
- Relaunched DosePop.com (Executing On telehealth healthcare technology diversification strategy)
“Veri Medtech (VRHI) continues to be a market leading healthcare platform enabling patients and doctors to seamless connect. In Q1, Veri Medtech (VRHI) successfully relaunched its industry-leading Veriheal.com healthcare technology platform, while simultaneously executing on strategic diversification via its relaunch also of DosePop.com. LifeMD, Ro and HIMS are key competitive barometers of the future of healthcare, and with
About Veri Medtech (OTC Markets: VRHI): Veri Medtech is a publicly-traded healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With a strong integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models. With a commitment to innovation and patient-centric care, Veri MedTech continues to expand its services and reach, aiming to make personalized healthcare more accessible and effective for all. For more information, please visit: www.VeriMedTech.com
About Veriheal: Veriheal, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”) is a healthcare technology company on a mission to help real people get real medicine. For more information, please visit: www.Veriheal.com
About DosePop: DosePop, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), provides a one-stop healthcare technology platform for mental and physical health, all designed to empower you to take charge of your well-being. From weight loss solutions to anti-aging, our treatments are backed by science and administered by licensed professionals. For more information, please visit: www.DosePop.com
About Global Telemedicine: The global telemedicine market size was valued at USD 114.98 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of
Forward Looking Statements: Cautionary Note Regarding Forward-Looking Statements: This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Veri Medtech (OTC: "VRHI") and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

PR Contact: pr@verimedtech.com